Explore
Validate
LearnMAB4391-100
antibody from R&D Systems
Targeting: CCL22
A-152E5.1, ABCD-1, DC/B-CK, MDC, MGC34554, SCYA22, STCP-1
ELISA
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB4391-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Mouse CCL22/MDC Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects mouse CCL22/MDC in ELISAs and Western blots. In Western blots, this antibody shows 25% cross-reactivity with recombinant viral MIP-II and no cross-reactivity with rmCCL1, 2, 3, 4, 6, 7, CCL9/10/MIP-1 gamma , 11, 12, 19, 20, 21, 22, 24, 25, 27, rhCCL1, 2, 3, 4, 5, 7, 8, 11, 13, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 28, or rrCCL20.
- Reactivity
- Mouse
- Host
- Rat
- Conjugate
- Unconjugated
- Antigen sequence
O88430- Isotype
- IgG
- Antibody clone number
- 158132
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Response patterns of cytokines/chemokines in two murine strains after irradiation.
Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway.
CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling.
iNKT cells require CCR4 to localize to the airways and to induce airway hyperreactivity.
Zhang M, Yin L, Zhang K, Sun W, Yang S, Zhang B, Salzman P, Wang W, Liu C, Vidyasagar S, Zhang L, Ju S, Okunieff P, Zhang L
Cytokine 2012 May;58(2):169-77
Cytokine 2012 May;58(2):169-77
Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway.
Kearley J, Buckland KF, Mathie SA, Lloyd CM
American journal of respiratory and critical care medicine 2009 May 1;179(9):772-81
American journal of respiratory and critical care medicine 2009 May 1;179(9):772-81
CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling.
Kearley J, Robinson DS, Lloyd CM
The Journal of allergy and clinical immunology 2008 Sep;122(3):617-24.e6
The Journal of allergy and clinical immunology 2008 Sep;122(3):617-24.e6
iNKT cells require CCR4 to localize to the airways and to induce airway hyperreactivity.
Meyer EH, Wurbel MA, Staton TL, Pichavant M, Kan MJ, Savage PB, DeKruyff RH, Butcher EC, Campbell JJ, Umetsu DT
Journal of immunology (Baltimore, Md. : 1950) 2007 Oct 1;179(7):4661-71
Journal of immunology (Baltimore, Md. : 1950) 2007 Oct 1;179(7):4661-71
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Chemotaxis Induced by CCL22/MDC and Neutralization by Mouse CCL22/MDC Antibody. Recombinant Mouse CCL22/MDC (Catalog # 439-MD) chemoattracts the BaF3 mouse pro-B cell line transfected with human CCR4 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse CCL22/MDC (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse CCL22/MDC Monoclonal Antibody (Catalog # MAB4391). The ND50 is typically 0.4-2.0 µg/mL.
